Skip to main content
Erschienen in: Nuclear Medicine and Molecular Imaging 2/2014

01.06.2014 | Original Article

The Role of 18 F-FDG PET/CT in Assessing Therapy Response in Cervix Cancer after Concurrent Chemoradiation Therapy

verfasst von: Jiyoun Choi, Hyun Jeong Kim, Yong Hyu Jeong, Jae-Hoon Lee, Arthur Cho, Mijin Yun, Jong Doo Lee, Yong Bae Kim, Young Tae Kim, Won Jun Kang

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine whether persisting cervical fluorodeoxyglucose (FDG) uptake after concurrent chemoradiotherapy (CCRT) for cervical cancer can reflect residual malignancy.

Methods

F-FDG PET/CT was performed before and after CCRT in 136 patients with cervical cancer. The maximum and mean standardized uptake values (SUVmax and SUVmean) were recorded from PET/CT scans performed pre- and post-treatment. SUVs were correlated with treatment response after CCRT. Final treatment response was determined by MRI and further follow-up PET/CT. One hundred four of 136 patients underwent pelvic MRI, and 32 of 136 patients underwent further follow-up PET/CT. Patients were classified into two categories: patients with residual tumor or patients without residual tumor (complete responder). Pre- and post-treatment serum squamous cell carcinoma antigen (SCC) levels were also recorded for comparison. The optimal cutoff value of SUVmax for predicting residual cervical tumor was determined using receiver-operating characteristic (ROC) analysis.

Results

Of 136 patients, 124 showed complete response on further follow-up studies and 12 were confirmed to have residual tumor. The post-treatment SUVmax and pre-/post-treatment SUVmean of complete responders were significantly lower than those of patients with residual tumor: 2.5 ± 0.8 and 7.2 ± 4.2/1.9 ± 0.7 for complete responders and 5.7 ± 2.6 and 12.8 ± 6.9/3.7 ± 0.7 for patients with residual tumor (p < 0.05). The pre-treatment SUVmax and pre-/post-treatment serum SCC levels of the complete responders tended to be lower than those of patients with residual tumor, but this did not have statistical significance. Using ROC analysis, an optimal cutoff SUVmax of 4.0 on the post-treatment PET/CT yielded a sensitivity, specificity, positive predictive value, and negative predictive value of 92 %, 94 %, 61 %, and 99 %, respectively (p < 0.001).

Conclusions

Persistent cervical FDG uptake in18F-FDG PET/CT after CCRT for cervical cancer may be caused by residual tumor or post-therapy inflammation. A higher cutoff SUVmax than conventional criteria for cervical cancer in post-CCRT PET/CT might help to detect residual tumor.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;59:225–49.PubMedCrossRef Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;59:225–49.PubMedCrossRef
2.
Zurück zum Zitat Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet. 2009;105:103–4.CrossRef Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet. 2009;105:103–4.CrossRef
3.
Zurück zum Zitat Patel CN, Nazir SA, Khan Z, Gleeson FV, Bradley KM. 18 F-FDG PET/CT of cervical carcinoma. AJR Am J Roentgenol. 2011;196(5):1225–33.PubMedCrossRef Patel CN, Nazir SA, Khan Z, Gleeson FV, Bradley KM. 18 F-FDG PET/CT of cervical carcinoma. AJR Am J Roentgenol. 2011;196(5):1225–33.PubMedCrossRef
4.
Zurück zum Zitat Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol. 2007;25:2952–65.PubMedCrossRef Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol. 2007;25:2952–65.PubMedCrossRef
5.
Zurück zum Zitat Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004;22(5):872–80.PubMedCrossRef Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004;22(5):872–80.PubMedCrossRef
6.
Zurück zum Zitat Sommers GM, Grigsby PW, Perez CA, Camel HM, Kao MS, Galakatos AE, et al. Outcome of recurrent cervical carcinoma following definitive irradiation. Gynecol Oncol. 1989;35(2):150–5.PubMedCrossRef Sommers GM, Grigsby PW, Perez CA, Camel HM, Kao MS, Galakatos AE, et al. Outcome of recurrent cervical carcinoma following definitive irradiation. Gynecol Oncol. 1989;35(2):150–5.PubMedCrossRef
7.
Zurück zum Zitat Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol. 2001;19(17):3745–9.PubMed Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol. 2001;19(17):3745–9.PubMed
8.
Zurück zum Zitat Jacobs AJ, Faris C, Perez CA, Kao MS, Galakatos A, Camel HM. Short-term persistence of carcinoma of the uterine cervix after radiation: an indicator of longterm prognosis. Cancer. 1986;57(5):944–50.PubMedCrossRef Jacobs AJ, Faris C, Perez CA, Kao MS, Galakatos A, Camel HM. Short-term persistence of carcinoma of the uterine cervix after radiation: an indicator of longterm prognosis. Cancer. 1986;57(5):944–50.PubMedCrossRef
9.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRef Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRef
10.
Zurück zum Zitat Lee M, Lee Y, Hwang KH, Choe W, Park CY. Usefulness of F-18 FDG PET/CT in Assessment of Recurrence of Cervical Cancer After Treatment. Nucl Med Mol Imaging. 2011;45(2):111–6.CrossRef Lee M, Lee Y, Hwang KH, Choe W, Park CY. Usefulness of F-18 FDG PET/CT in Assessment of Recurrence of Cervical Cancer After Treatment. Nucl Med Mol Imaging. 2011;45(2):111–6.CrossRef
11.
Zurück zum Zitat Bjurberg M, Kjellén E, Ohlsson T, Ridderheim M, Brun E. FDG-PET in cervical cancer: staging, re-staging and follow-up. Acta Obstet Gynecol Scand. 2007;86:1385–91.PubMedCrossRef Bjurberg M, Kjellén E, Ohlsson T, Ridderheim M, Brun E. FDG-PET in cervical cancer: staging, re-staging and follow-up. Acta Obstet Gynecol Scand. 2007;86:1385–91.PubMedCrossRef
12.
Zurück zum Zitat Bural GG, Shriaknthan S, Houseni M, Alavi A. FDG-PET is useful in staging and follow-up of primary uterine cervical lymphoma. Clin Nucl Med. 2007;32:748–50.PubMedCrossRef Bural GG, Shriaknthan S, Houseni M, Alavi A. FDG-PET is useful in staging and follow-up of primary uterine cervical lymphoma. Clin Nucl Med. 2007;32:748–50.PubMedCrossRef
13.
Zurück zum Zitat Loft A, Berthelsen AK, Roed H, Ottosen C, Lundvall L, Knudsen J, et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol. 2007;106:29–34.PubMedCrossRef Loft A, Berthelsen AK, Roed H, Ottosen C, Lundvall L, Knudsen J, et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol. 2007;106:29–34.PubMedCrossRef
14.
Zurück zum Zitat Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol. 2004;22(11):2167–71.PubMedCrossRef Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol. 2004;22(11):2167–71.PubMedCrossRef
15.
Zurück zum Zitat Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA. 2007;298:2289–95.PubMedCrossRef Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA. 2007;298:2289–95.PubMedCrossRef
16.
Zurück zum Zitat Sala E, Rockall AG, Freeman SJ, Mitchell DG, Reinhold C. The added role of MR imaging in treatment stratification of patients with gynecologic malignancies: what the radiologist needs to know. Radiology. 2013;266:717–40.PubMedCrossRef Sala E, Rockall AG, Freeman SJ, Mitchell DG, Reinhold C. The added role of MR imaging in treatment stratification of patients with gynecologic malignancies: what the radiologist needs to know. Radiology. 2013;266:717–40.PubMedCrossRef
17.
Zurück zum Zitat Hardt N, van Nagell JR, Hanson M, Donaldson E, Yoneda J, Maruyama Y. Radiation-induced tumor regression as a prognostic factor in patients with invasive cervical cancer. Cancer. 1982;49:35–9.PubMedCrossRef Hardt N, van Nagell JR, Hanson M, Donaldson E, Yoneda J, Maruyama Y. Radiation-induced tumor regression as a prognostic factor in patients with invasive cervical cancer. Cancer. 1982;49:35–9.PubMedCrossRef
18.
Zurück zum Zitat Hong JH, Chen MS, Lin FJ, Tang SG. Prognostic assessment of tumor regression after external irradiation for cervical cancer. Int J Radiat Oncol Biol Phys. 1992;22:913–7.PubMedCrossRef Hong JH, Chen MS, Lin FJ, Tang SG. Prognostic assessment of tumor regression after external irradiation for cervical cancer. Int J Radiat Oncol Biol Phys. 1992;22:913–7.PubMedCrossRef
19.
Zurück zum Zitat Lee KC, Moffat BA, Schott AF, Layman R, Ellingworth S, Juliar R, et al. Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res. 2007;13:443–50.PubMedCrossRef Lee KC, Moffat BA, Schott AF, Layman R, Ellingworth S, Juliar R, et al. Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res. 2007;13:443–50.PubMedCrossRef
20.
Zurück zum Zitat Pickles MD, Gibbs P, Lowry M, Turnbull LW. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging. 2006;24:843–7.PubMedCrossRef Pickles MD, Gibbs P, Lowry M, Turnbull LW. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging. 2006;24:843–7.PubMedCrossRef
21.
Zurück zum Zitat Lee JE, Huh SJ, Nam H, Ju SG. Early response of patients undergoing concurrent chemoradiotherapy for cervical cancer: a comparison of PET/CT and MRI. Ann Nucl Med. 2013;27(1):37–45.PubMedCrossRef Lee JE, Huh SJ, Nam H, Ju SG. Early response of patients undergoing concurrent chemoradiotherapy for cervical cancer: a comparison of PET/CT and MRI. Ann Nucl Med. 2013;27(1):37–45.PubMedCrossRef
22.
Zurück zum Zitat Grigsby PW. PET/CT imaging to guide cervical cancer therapy. Future Oncol. 2009;5(7):953–8.PubMedCrossRef Grigsby PW. PET/CT imaging to guide cervical cancer therapy. Future Oncol. 2009;5(7):953–8.PubMedCrossRef
23.
Zurück zum Zitat Soret M, Bacharach SL, Buvat I. Parital –volume effect in PET tumor imaging. J Nucl Med. 2007;48;932-45. Soret M, Bacharach SL, Buvat I. Parital –volume effect in PET tumor imaging. J Nucl Med. 2007;48;932-45.
24.
Zurück zum Zitat Bolli JN, Doering DL, Bosscher JR, Day TG, Rao CV, Owens K, et al. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 1994;55:169–73.PubMedCrossRef Bolli JN, Doering DL, Bosscher JR, Day TG, Rao CV, Owens K, et al. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 1994;55:169–73.PubMedCrossRef
25.
Zurück zum Zitat Bonfrer JMG, Gaarenstroom KN, Korse CM, Van Bunningen BNFM, Kenemans P. Cyfra 21–1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen. Anticancer Res. 1997;17:2329–34.PubMed Bonfrer JMG, Gaarenstroom KN, Korse CM, Van Bunningen BNFM, Kenemans P. Cyfra 21–1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen. Anticancer Res. 1997;17:2329–34.PubMed
26.
Zurück zum Zitat Brioschi PA, Bischof P, Delafosse C, Krauer F. Squamous cell carcinoma antigen (SCC-A) values related to clinical outcome of pre-invasive and invasive cervical carcinoma. Int J Cancer. 1991;47:376–9.PubMedCrossRef Brioschi PA, Bischof P, Delafosse C, Krauer F. Squamous cell carcinoma antigen (SCC-A) values related to clinical outcome of pre-invasive and invasive cervical carcinoma. Int J Cancer. 1991;47:376–9.PubMedCrossRef
27.
Zurück zum Zitat Hong JH, Tsai CS, Chang JT, Wang CC, Lai CH, Lee SP, et al. The prognostic significance of pre-and post-treatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41:823–30.PubMedCrossRef Hong JH, Tsai CS, Chang JT, Wang CC, Lai CH, Lee SP, et al. The prognostic significance of pre-and post-treatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41:823–30.PubMedCrossRef
Metadaten
Titel
The Role of 18 F-FDG PET/CT in Assessing Therapy Response in Cervix Cancer after Concurrent Chemoradiation Therapy
verfasst von
Jiyoun Choi
Hyun Jeong Kim
Yong Hyu Jeong
Jae-Hoon Lee
Arthur Cho
Mijin Yun
Jong Doo Lee
Yong Bae Kim
Young Tae Kim
Won Jun Kang
Publikationsdatum
01.06.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Nuclear Medicine and Molecular Imaging / Ausgabe 2/2014
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-013-0248-y

Weitere Artikel der Ausgabe 2/2014

Nuclear Medicine and Molecular Imaging 2/2014 Zur Ausgabe